Showing results (41-50 of 142) with videos related to
Sort By:
Pageof 15
Journal of Mental Health (Abingdon, England)|September 19, 2015
The relationship between sleep disturbance in pregnancy and persistent common mental disorder in the perinatal period (sleep disturbance and persistent CMD)Joanna Vaz MacLean, Alexandre Faisal-Cury, Ya-Fen Chan, et al.Transplantation and Cellular Therapy|September 9, 2023
INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic LeukemiaAdam J Lamble, Amy Moskop, Michael A Pulsipher, et al.Investigational New Drugs|July 12, 2008
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapyChristopher Lieu, Laura Chow, A Scott Pierson, et al.Pediatric Blood & Cancer|July 10, 2021
A prospective survey study of lower urinary tract dysfunction in childhood cancer survivors after vincristine and/or doxorubicin chemotherapySarah L Hecht, Alan Quach, Dexiang Gao, et al.Cancer|February 25, 2023
Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemiaManon Queudeville, Anthony S Stein, Franco Locatelli, et al.Leukemia & Lymphoma|August 1, 2023
Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a reviewFranco Locatelli, Bijal Shah, Tracy Thomas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2008
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomasLia Gore, Mace L Rothenberg, Cindy L O'Bryant, et al.British Journal of Clinical Pharmacology|November 15, 2018
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignanciesYing Ou, Yang Xu, Lia Gore, et al.Molecular Cancer Therapeutics|December 17, 2008
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumorsElaine T Lam, Cindy L O'Bryant, Michele Basche, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working GroupLia Gore, S Percy Ivy, Frank M Balis, et al.Pageof 15